HC Wainwright Has Optimistic Opinion of PTGX FY2026 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) – Analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Protagonist Therapeutics in a research note issued on Friday, November 6th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $4.61 per share for the year, up from their previous forecast of $4.00. HC Wainwright currently has a “Buy” rating and a $221.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $5.52 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at $0.31 EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at $0.67 EPS, FY2029 earnings at $7.60 EPS and FY2030 earnings at $7.78 EPS.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.57. The firm had revenue of $274.41 million for the quarter, compared to analyst estimates of $238.49 million. Protagonist Therapeutics had a return on equity of 42.83% and a net margin of 62.04%.

PTGX has been the topic of several other reports. BMO Capital Markets upped their price objective on shares of Protagonist Therapeutics from $178.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 1st. Truist Financial lifted their target price on shares of Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Citigroup lifted their target price on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Wolfe Research reissued an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, August 31st. Finally, Barclays increased their price target on shares of Protagonist Therapeutics from $153.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $166.67.

Check Out Our Latest Research Report on PTGX

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $134.86 on Tuesday. The business’s fifty day moving average is $140.89 and its 200 day moving average is $118.61. The firm has a market cap of $8.80 billion, a price-to-earnings ratio of 28.87 and a beta of 1.21. Protagonist Therapeutics has a 52-week low of $77.00 and a 52-week high of $160.81.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Protagonist Therapeutics during the 2nd quarter valued at about $1,263,535,000. Janus Henderson Group PLC grew its stake in shares of Protagonist Therapeutics by 9.1% in the first quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company’s stock worth $304,866,000 after acquiring an additional 241,546 shares during the period. Johnson & Johnson bought a new stake in shares of Protagonist Therapeutics in the second quarter worth approximately $300,220,852. Jupiter Topco LLC purchased a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $261,039,000. Finally, Bank of America Corp DE purchased a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $162,357,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Protagonist Therapeutics

In related news, CFO Asif Ali sold 58,629 shares of the business’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the sale, the chief financial officer owned 59,003 shares of the company’s stock, valued at $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 63,548 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total value of $9,289,446.64. Following the completion of the sale, the chief executive officer directly owned 522,968 shares in the company, valued at approximately $76,447,462.24. This represents a 10.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 183,629 shares of company stock valued at $26,552,987 in the last three months. Corporate insiders own 5.19% of the company’s stock.

Key Protagonist Therapeutics News

These are some of the PTGX news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its 2026 EPS estimate to $4.61 from $4.00 and improved several later-year forecasts, including moving its 2028 outlook from a loss to a profit. It also sharply increased its 2029 and 2030 EPS estimates. The firm reiterated its Buy rating and $221 price target. These changes may support sentiment, although much of the projected improvement is several years away. HC Wainwright analyst estimates
  • Neutral Sentiment: A short-interest item describes a “significant increase” but reports total short interest of zero shares and a short-interest ratio of 0.0 days. The figures are inconsistent, so the report offers no reliable indication of meaningful short-selling pressure. Short-interest report

Protagonist Therapeutics Company Profile

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Recommended Stories

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.